Ogenix
Missing: Ogenix's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Ogenix's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Ogenix
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Ogenix is included in 2 Expert Collections, including Diabetes.
Diabetes
1,904 items
Medical Devices
3,088 items
Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)
Latest Ogenix News
Apr 5, 2012
Share / Apr 4, 2012 at 10:21 AM Ogenix has received a warning letter from the U.S. Food and Drug Administration related to its Epiflo oxygen therapy medical device for wound healing. The FDA’s warning letter details six specific violations uncovered during an inspection of the Florida-based company’s manufacturing facility in Beachwood, Ohio. Most of the violations deal with issues that involve documentation and record keeping. For example, the FDA cites Ogenix for failing to include in its analysis risks involving strength and durability of the Epiflo. Some field complaints cited the breakage of locks on the device, but Ogenix’s analysis didn’t reflect these risks, according to the letter. Advertisement The FDA also cited Ogenix for failing to perform adequate testing of design changes to the device before those changes were implemented. Craig Davis, a managing director with Ogenix, called the contents of the warning letter “pretty routine stuff.” “Every company gets audited by the FDA periodically and this was just the result of that audit,” he said. The letter instructed Ogenix to reply to the FDA with specific steps the company has taken to address the violations noted in the warning letter. Davis said Ogenix has already done so. The Epiflo device is made of a small oxygen concentrator and a delivery tube. It’s used in conjunction with a wound dressing “to continuously blanket the wound with near-100 percent oxygen,” according to the company. The device is cleared by the FDA for treatment of diabetic foot ulcers, bed sores, surgical wounds and burns.
Ogenix Frequently Asked Questions (FAQ)
Where is Ogenix's headquarters?
Ogenix's headquarters is located at 23230 Chagrin Blvd, Cleveland.
Who are Ogenix's competitors?
Competitors of Ogenix include MicroTransponder, Noraker, Endologix, Acelity, Entellus Medical and 13 more.
Compare Ogenix to Competitors
CryoPen is a developer and manufacturer of state-of-the art medical devices and aesthetic treatment systems. CryoPen is committed to delivering the most effective, and profitable solutions available to healthcare providers, physicians of all specialties, and medical spas. The company's product portfolio aims to enable physicians to provide a higher quality of care and offer their patients a more diverse array of treatments while generating a substantial revenue stream for their practice. CryoPen's product set addresses a multitude of treatment applications such as laser hair removal, skin rejuvenation, cryosurgery, cellulite reduction, vascular lesions, pigmented lesions, acne, psoriasis, fine lines & wrinkles, scar and tattoo removal, photo facials, and skin tightening. With a dedication to the research and development of technologically advanced devices and equipment, every CryoPen product is designed to create a better patient experience, consistent clinical outcomes, and economic impact on the bottom line of their practice.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.
NanoPowers aims to develop artificial muscles for various implant indications. The Company has developed several animal proof of concepts, and is entering preclinical stages with devices aimed for the treatment of urinary and fecal incontinences.
Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.
Researcher and developer of a minimally invasive, encapsulated cellular transplant device for the treatment of diabetes. The company sold its assets to Novocell.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.